Publications

Increased vaccine sensitivity of an emerging SARS-CoV-2 variant.

Author(s): Lewnard JA, Hong V, Kim JS, Shaw SF, Lewin B, Takhar H, Lipsitch M, Tartof SYJournal: Nat CommunPMID: 37386005 June 2023

Host immune responses are a key source of selective pressure driving pathogen evolution. Emergence of many SARS-CoV-2 lineages has been…

Hospitalization and Emergency Department Encounters for COVID-19 After Paxlovid Treatment – California, December 2021-May 2022.

Author(s): Malden DE, Hong V, Lewin BJ, Ackerson BK, Lipsitch M, Lewnard JA, Tartof SYJournal: MMWR Morb Mortal Wkly RepPMID: 35737591 June 2022

Nirmatrelvir/ritonavir (Paxlovid) is a combination protease inhibitor that blocks replication of SARS-CoV-2 (the virus that causes COVID-19) and has been…

Clinical outcomes associated with SARS-CoV-2 Omicron (B.1.1.529) variant and BA.1/BA.1.1 or BA.2 subvariant infection in southern California.

Author(s): Lewnard JA, Hong VX, Patel MM, Kahn R, Lipsitch M, Tartof SYJournal: Nat MedPMID: 35675841 June 2022

Epidemiologic surveillance has revealed decoupling of COVID-19 hospitalizations and deaths from case counts following emergence of the Omicron (B.1.1.529) SARS-CoV-2…

Clinical outcomes among patients infected with Omicron (B.1.1.529) SARS-CoV-2 variant in southern California

Author(s): Lewnard JA, Hong VX, Patel MM, Kahn R, Lipsitch M, Tartof SYJournal: medRxiv January 2022

The Omicron (B.1.1.529) variant of SARS-CoV-2 has rapidly achieved global dissemination, accounting for most infections in the United States by…

Combining genomics and epidemiology to track mumps virus transmission in the United States.

Author(s): Wohl S, Metsky HC, Schaffner SF, Piantadosi A, Burns M, Lewnard JA, Chak B, Krasilnikova LA, Siddle KJ, Matranga CB, Bankamp B, Hennigan S, Sabina B, Byrne EH, McNall RJ, Shah RR, Qu J, Park DJ, Gharib S, Fitzgerald S, Barreira P, Fleming S, Lett S, Rota PA, Madoff LC, Yozwiak NL, MacInnis BL, Smole S, Grad YH, Sabeti PCJournal: PLoS BiolPMID: 32045407 February 2020

Unusually large outbreaks of mumps across the United States in 2016 and 2017 raised questions about the extent of mumps…

Increased vaccine sensitivity of an emerging SARS-CoV-2 variant.

Hospitalization and Emergency Department Encounters for COVID-19 After Paxlovid Treatment – California, December 2021-May 2022.

Clinical outcomes associated with SARS-CoV-2 Omicron (B.1.1.529) variant and BA.1/BA.1.1 or BA.2 subvariant infection in southern California.

Clinical outcomes among patients infected with Omicron (B.1.1.529) SARS-CoV-2 variant in southern California

Combining genomics and epidemiology to track mumps virus transmission in the United States.

Pneumococcal conjugate vaccines in different settings – Authors’ reply.

The use of test-negative controls to monitor vaccine effectiveness: a systematic review of methodology.

Accounting for unobserved and differential susceptible time at risk in retrospective studies: response to Dean (2019).

Making sense of differences in pneumococcal serotype replacement.

Measurement of Vaccine Direct Effects Under the Test-Negative Design.